13 Hanover Square
109 articles with Hikma Pharmaceuticals
Arguments regarding the Purdue Pharma opioid settlement continue to be heard in court, Natera battles a class-action lawsuit, Walgreens is involved in a public nuisance suit and more.
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara®, in the United States.
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.
Hikma Pharmaceuticals PLC and Arecor Limited announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma's generic version of Vascepa ®1 (icosapent ethyl) 1gm does not infringe any valid claim of six key Amar
Premier Inc. ProvideGx™ Program Partners with Hikma Pharmaceuticals to Secure the Supply of Two Drugs Essential for COVID-19 Patient Care
Premier Inc., through its ProvideGx™ program, has partnered with Hikma Pharmaceuticals PLC to supply amiodarone and sterile water to healthcare providers, helping to stabilize the long-term supply of two medications vital for COVID-19 patient care.
Campaign will help address significant increase in demand caused by COVID-19 related job losses and furloughs
Hikma Ventures invests in Altoida, Inc., a predictive digital biomarker company using AI and AR to help predict brain diseases with up to 94% accuracy
Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has invested in Altoida, Inc. following the company's $6.3 million Series A round in 2019..
Hikma Pharmaceuticals PLC confirms that the United States District Court for the District of Nevada has ruled that Hikma's generic version of Amarin Corporation's Vascepa® 1 gm capsules does not infringe six United States Patents, as asserted by Amarin, because the asserted claims of these patents were held to be invalid.
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP 30mg/mL, 1mL Fill/2mL Vials Due to the Potential Presence of Small Particulates
Hikma Pharmaceuticals PLC, announces that its subsidiary Hikma Pharmaceuticals USA Inc. is voluntarily extending its previously-announced recall of certain lots of Ketorolac Tromethamine Injection USP 30mg/mL, 1mL fill/2mL vials to the medical facility and retail levels.
Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
Builds on Hikma's leading position in nasal sprays and strong specialty salesforce
This order by the U.S. Supreme Court ensures that the '610 patent will remain exclusive at least through November 2, 2027, absent further challenges from other parties.
California, Other States and Organizations Develop Schemes to Enter Generic Market and Drive Down...
1/10/2020The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget.
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
Product designed to provide safer, more immediate treatment option for patients
Arecor and Hikma Announce Exclusive Agreement to Develop and Commercialise Ready-To-Use Medicine Using Arestat™ TechnologyProduct designed to provide safer, more immediate treatment option for patients
Hikma Pharmaceuticals PLC and Arecor Ltd announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
Marks first key milestone for the Civica Rx-Hikma partnership, which is set to supply 14 essential medicines to US hospitals and patients
Hikma Ventures leads Series A financing for development of Winterlight Labs' AI vocal technology to detect central nervous system disorders and track efficacy of treatments
Hikma Pharmaceuticals PLC, announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.
Heparin Sodium Injection in a ready-to-use syringe is the first product using Hikma's new injectable manufacturing capability [17-September-2019] LONDON , Sept. 17, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P) the multinational pharmaceutical company, has l